Zubair Khalid

Virologist/Molecular Biologist | Veterinarian | Bioinformatician

Conventional & Molecular Virology • Vaccine Development • Computational Biology

Dr. Zubair Khalid is a veterinarian and virologist specializing in conventional and molecular virology, vaccine development, and computational biology. Dedicated to advancing animal health through innovative research and multi-omics approaches.

Dr. Zubair Khalid - Veterinarian, Virologist, and Vaccine Development Researcher specializing in Computational Biology, Multi-omics, Animal Health, and Infectious Disease Research

Category: Guides

Antibody Structure

Antibodies are Y shaped glycoproteins produced by B cells that recognize and bind specific antigens with high affinity. This guide explains the key structural features of antibodies, how these features relate to function, and practical considerations for researchers, biotechnologists, and students who work with antibodies in assays, diagnostics, or therapeutics. Understanding antibody structure allows you to design better reagents, interpret binding data, and avoid common pitfalls. The foundational reference for antibody biology is the NCBI Bookshelf which contains authoritative chapters on immunoglobulin structure.

A complete picture of antibody structure includes the four polypeptide chain composition, the division into variable and constant domains, and the functional regions of Fab and Fc. The variable domains contain hypervariable complementary determining regions (CDRs) that form the antigen binding site. For practical use in the laboratory, you need to know how these domains are assembled, what modifications matter, and how to validate structural integrity. The EMBL EBI Training portal provides resources for analyzing antibody sequences and structures in silico.

At a Glance: Antibody Structure

Component Description Function Key Regions
Heavy chain (H) Larger polypeptide, 50 70 kDa, five isotypes (IgG, IgA, IgM, IgD, IgE) Provides framework for antigen recognition and effector functions VH, CH1, CH2, CH3, hinge
Light chain (L) Smaller polypeptide, 25 kDa, kappa or lambda Contributes to antigen binding VL, CL
Disulfide bonds Covalent bridges between heavy or light chains Stabilize Y shape and interchain connections Interchain and intrachain
Fab (Fragment antigen binding) Two identical arms each comprising one light chain and VH CH1 of heavy chain Binds antigen CDR loops, framework regions
Fc (Fragment crystallizable) Stem of Y formed by paired CH2 and CH3 domains Mediates effector functions (complement, Fc receptor binding) Glycosylation site, FcRn binding
Hinge Flexible region between Fab and Fc Allows independent arm movement Proline rich, disulfide bonds
CDRs Six hypervariable loops (three per heavy, three per light) Directly contact antigen 5 15 residues each

The table above summarizes the essential structural parts. Each region has been studied extensively, and the NCBI Bookshelf offers detailed reviews on antibody domain organization.

Core Structural Concepts

Antibodies belong to the immunoglobulin superfamily. Each antibody monomer is composed of two identical heavy chains and two identical light chains. The heavy chains come in five isotypes that determine the antibody class and downstream immune functions. Light chains are either kappa or lambda and pair with any heavy chain isotype. The chains are held together by disulfide bonds, with the number and location of these bonds varying by isotype, as noted in resources from the Galaxy Training Network which includes workflows for analyzing disulfide connectivity.

The variable domains (VH and VL) each contain three CDRs. The six CDRs together create a binding surface that can be remarkably specific. The surrounding framework regions (FR1 to FR4) support the CDR loops. The constant domains (CH1, CH2, CH3, CL) define the antibody class and mediate effector functions. The hinge region between CH1 and CH2 provides flexibility, allowing the two Fab arms to rotate and bind antigens at different distances. A recent study published in Nature Communications used an antibody to reveal a conformational latch that regulates dimerization in herpesvirus proteases, illustrating how antibody paratopes can recognize three dimensional shapes.

Glycosylation at the conserved N linked site in CH2 (usually Asn 297) is critical for Fc receptor binding and complement activation. The glycan composition varies with expression system, antibody isotype, and cell culture conditions. If you produce recombinant antibodies, you must consider glycan effects on stability and function.

Decision Points: Choosing or Engineering Antibodies

When you select or engineer an antibody for an experiment or therapeutic application, you face several structural decisions.

Monoclonal versus polyclonal. Monoclonal antibodies are identical and target a single epitope. Polyclonal antibodies are a mixture that recognizes multiple epitopes on the same antigen. For quantitative assays, monoclonal antibodies provide consistency. For immunoprecipitation or western blotting, polyclonal antibodies can be more sensitive.

Full length versus fragments. Full length IgG is standard for most applications, but Fab fragments are useful when you need to avoid Fc binding or reduce steric hindrance. Single chain variable fragments (scFv) link VH and VL with a peptide and are widely used in phage display and CAR T cells. The antibody drug conjugate brentuximab vedotin, discussed in Leukemia, uses a chimeric monoclonal antibody that targets CD30. Understanding its structure helps design next generation conjugates.

Species and humanization. Mouse antibodies are immunogenic in humans. Chimeric antibodies (mouse variable domains on human constant domains) reduce this. Humanized antibodies replace most mouse framework regions with human sequences while retaining mouse CDRs. Fully human antibodies come from transgenic mice or phage display libraries. The structural compatibility between variable and constant domains must be maintained to preserve binding affinity.

Effector function requirements. If you need antibody dependent cellular cytotoxicity or complement activation, choose an isotype with strong Fc receptor binding (e.g., human IgG1). If you only want blocking, use IgG4 or an aglycosylated IgG1. Intravenous immunoglobulin therapy, reviewed in Biomedicine and Pharmacotherapy, relies on the Fc region of pooled IgG to modulate immune responses in viral infections.

Practical Workflow: Characterizing Antibody Structure

Follow this sequence to characterize the structure of a novel antibody or to confirm the identity of a recombinant antibody. The order is designed to move from sequence to structural models to experimental validation.

Step 1: Obtain the Sequence

Sequence the antibody genes from hybridoma cells, single B cells, or expression plasmids. Use primers for conserved regions in the constant domains. Submit the samples for Sanger sequencing or use next generation sequencing from the NCBI Sequence Read Archive as a source for B cell repertoire data. Assemble the VH and VL sequences and translate them to protein sequences.

Step 2: Model the Variable Domains

Use homology modeling with well resolved antibody templates (e.g., from the Protein Data Bank). Align the CDR canonical classes. Software tools from the EMBL EBI Training can guide you through the modeling pipeline. Check for unusual CDR lengths or cysteines that might affect folding.

Step 3: Predict Post Translational Modifications

Scan the sequence for N linked glycosylation motifs (Asn Xaa Ser/Thr) in the constant region and variable domains. Also look for deamidation or oxidation sensitive residues in CDRs. The Bioconductor project provides packages for analyzing protein modifications from mass spectrometry data.

Step 4: Express and Purify the Antibody

Choose an expression system (mammalian cells for correct glycosylation, bacterial cells for Fab only). Transfect or transduce cells, purify using protein A or protein G affinity chromatography. Analyze by reducing and nonreducing SDS PAGE to confirm heavy and light chain assembly and disulfide bond formation.

Step 5: Validate Structure Experimentally

Measure the binding affinity using surface plasmon resonance or biolayer interferometry. For crystallographic studies, set up crystallization screens and collect X ray diffraction data. Alternatively, use negative stain electron microscopy or hydrogen deuterium exchange mass spectrometry to map epitopes. For point of care diagnostics, the quality of antibodies is assessed in lateral flow assays, as described in Journal of Virological Methods for Usutu virus detection.

Step 6: Perform Quality Control

Test lot to lot consistency. Measure aggregation by size exclusion chromatography. Check for endotoxin contamination if the antibody will be used in vivo. The final structural integrity can be confirmed by peptide mapping or intact mass spectrometry.

Quality Checks for Antibody Structure

Before using an antibody in a critical experiment, run these checks.

  • SDS PAGE under reducing and nonreducing conditions: Confirm the presence of heavy chain (50 kDa) and light chain (25 kDa) and the absence of free thiols or aggregates.
  • Mass spectrometry: Verify the mass matches the predicted sequence and check for correct glycosylation.
  • Binding ELISA: Test against the intended antigen and against negative controls.
  • Thermal stability: Using differential scanning fluorimetry, measure the melting temperature. A stable Fab should have a Tm above 60 degrees Celsius.
  • Isoelectric focusing: Ensure the pI matches the calculated value. Isoelectric heterogeneity often indicates deamidation or other modifications.
  • Epitope binning: If multiple antibodies are available, test whether they compete for the same epitope. This is critical for sandwich immunoassays.

Common Mistakes

Ignoring glycosylation effects. Producing antibodies in bacterial systems yields aglycosylated Fc that cannot bind Fc receptors. This may be acceptable for Fab fragments but not for full length therapeutic antibodies. Always verify glycosylation status.

Assuming all isotypes are the same. Human IgG1, IgG2, IgG3, and IgG4 have different hinge lengths, disulfide bond patterns, and effector functions. Using the wrong isotype can lead to unexpected immune responses or instability.

Overlooking CDR loop conformations. CDR H3 is the most variable in length and structure. If homology modeling uses an incorrect canonical class for H3, the predicted binding surface will be wrong. Check the modeled structure against experimental data if available.

Using a single expression system. Some antibody sequences require a specific host strain to fold correctly. If you observe low yield or aggregation, try a different mammalian cell line or optimize the signal peptide. The Galaxy Training Network includes workflows for codon optimization and expression vector design.

Limits of Interpretation

Structural models from homology or deep learning are predictions, not experimental truths. They can misplace side chains or miss noncanonical conformations. X ray structures represent one conformation in a crystal lattice and may not capture solution dynamics. Glycosylation patterns vary between expression systems and even between batches, so the reported structure may not reflect your specific antibody. Affinity measurements depend on buffer, temperature, and antigen format. A high affinity antibody in one assay might show lower affinity in a different context.

Antibodies that target self antigens, such as anti NXP2 antibodies associated with inflammatory myopathy described in Rheumatology International, can have altered binding properties due to somatic mutations. Structural interpretation of autoantibodies must consider the possibility of atypical CDR lengths or framework changes.

Finally, gold based nanomaterials for antibody conjugation, reviewed in Advances in Colloid and Interface Science, can affect antibody structure through surface denaturation. Always characterize the antibody after conjugation, not just before.

Frequently Asked Questions

What are CDRs and why are they important? CDRs are the six hypervariable loops in the variable domains that directly contact the antigen. Their sequence and conformation determine the specificity and affinity of the antibody. Most antibody engineering efforts focus on modifying CDRs to improve binding.

What is the function of the Fc region? The Fc region, composed of paired CH2 and CH3 domains, interacts with immune receptors (Fc gamma receptors) and complement protein C1q. It also binds the neonatal Fc receptor (FcRn) which controls antibody half life. The Fc glycan is essential for these interactions.

How do antibody fragments differ from full length antibodies? Antibody fragments such as Fab, F(ab)2, scFv, and nanobodies lack the Fc region. They are smaller, often better at tissue penetration, and do not trigger effector functions. However, they have shorter half lives because they lack FcRn binding.

How does antibody structure influence therapeutic efficacy? The structure determines the antibody's distribution, half life, and ability to recruit immune cells. For example, an IgG1 with a functional Fc glycan can kill target cells through antibody dependent cellular cytotoxicity. An IgG4 with a S228P mutation prevents arm exchange and ensures stability. The hinge flexibility can affect how well the antibody binds clustered antigens.

References and Further Reading

Related Articles